Study finds possible new treatment of corneal ulcers in neurotrophic keratitis patients

Article

Italian biopharmaceutical company Dompé is researching recombinant human nerve growth factor (rhNGF) for the treatment of corneal ulcers in patients affected by neurotrophic keratitis.

Italy-Italian biopharmaceutical company Dompé is researching recombinant human nerve growth factor (rhNGF) for the treatment of corneal ulcers in patients affected by neurotrophic keratitis.

rhNGF is in clinical development in the REPARO study, which is being conducted at 39 centers in nine European countries. Preliminary data from Phase I of the study, involving patients affected by moderate or severe neurotrophic keratitis, demonstrates that rhNGF is well tolerated.

The study examined 18 patients (seven men and 11 women) suffering from moderate or severe neurotrophic keratitis resulting from diabetes, eye infections caused by the herpes virus, infections, neurosurgical interventions, and other related diseases, and who did not respond to currently available medical treatments.

The patients were divided into four groups. In the first group, patients were administered an eye drop solution for topical use at a dose of 10 µg/ml. In the second group, a simple vehicle was administered. In the third group, a dose of 20 µg/ml was given and, in the fourth group, a placebo was administered. At the end of the treatment, 11 patients had a notable improvement in corneal conditions. 

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Matt Jones, OD; Matt Burns, OD; and Joe Sugg, OD; detailed what optometrists can expect to change when HB 1353's regulations are enacted later this year.
Arkansas Optometric Association legislative cochairs Matt Jones, OD; Matt Burns, OD; and Joe Sugg, OD, discuss their involvement in their bill and provide context for its relevance.
Elise Kramer, OD, FAAO, FSLS, describes her take on a multidisciplinary approach to dry eye
Dana Shannon, OD, FAAO, shares pearls on spotting red flags in need of referral and enhancing patient care with follow-up compliance.
Dana Shannon, OD, FAAO, detailed a lecture she gave at the NOA Midwestern Symposium earlier this month.
CRU 2025 provided the latest insights regarding glaucoma, dry eye disease, retina, myopia, neurotrophic keratitis, and keratoconus.
Rachelle Lin, OD, MS, FAAO
Paul Karpecki, OD, FAAO
Melissa Barnett, OD, FAAO, FSLS, FBCLA, gave 2 presentations alongside other ODs and MDs at CRU 2025.
Rachelle Lin, OD, MS, FAAO, at CRU Eye Symposium 2025
© 2025 MJH Life Sciences

All rights reserved.